About Lamina
Lamina makes instruments for surgeons performing open operations. CoronaBlade follows a familiar surgical-instrument format.
Lamina is based in Oakland, California. Co-founder and CEO Paul Davison has more than 30 years of medical technology experience. Co-founder and CTO Jason Hegener has over 20 years in the field, including engineering and research and development.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Oct 2, 2026 | Oct 16, 2026 | $490,000of $5.0M target | 8 | $61,250 | Options, Simple Agreements for Future Equity (SAFEs)Rule 506(c) | Form D ↗ |
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Lamina
Lamina develops surgical instruments for open procedures. Its investment case rests on updating a familiar operating-room tool rather than creating an unfamiliar format. CoronaBlade gives that thesis a specific product.
The problem it targets
Lamina argues that open surgery still relies on tools built for another era. It defines the need around existing instruments used during open procedures. That framing makes modernization, rather than a new surgical workflow, the core opportunity.
What the product does
Lamina presents CoronaBlade as offering scalpel-like precision in a familiar surgical instrument. It also promotes a zero-capital barrier. Together, those claims target both product performance and adoption cost.
We wrote this summary from public statements by Lamina and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Lamina's Form D filed Oct 16, 2026.